Renato V. LaRocca

Norton Healthcare — United States

Immunology and Microbiology · Life Sciences

20h-index3.1kcitations81works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(32), Glioma Diagnosis and Treatment(27), CAR-T cell therapy research(15), RNA Interference and Gene Delivery(12), Cancer Research and Treatments(12)

Publications80 total

Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival
Human Vaccines & Immunotherapeutics·2025· 3 citedOpen Access
Clinical and descriptive characteristics associated with high-grade meningioma in a large clinical series
British Journal of Neurosurgery·2023· 1 citedOpen Access
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
Journal of Clinical Oncology·2023· 3 cited
Supplementary Data from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Supplementary Data 3 from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Supplementary Data 1 from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Data from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Supplementary Data 2 from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Supplementary Data 2 from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Data from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Supplementary Data 1 from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Supplementary Data 3 from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Supplementary Data from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
2023Open Access
Clinical and descriptive characteristics associated with high-grade meningioma in a large clinical series
Figshare·2023Open Access
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Journal of Experimental & Clinical Cancer Research·2022· 46 citedOpen Access
Phase 2 Study of AV-GBM-1 (a Tumor-initiating Cell Targeted Dendritic Cell Vaccine) in Newly Diagnosed Glioblastoma Patients: Safety and Efficacy Assessment
Research Square (Research Square)·2022· 1 citedOpen Access
Multifocal intradural extramedullary ependymoma, MYCN amplified: illustrative case
Journal of Neurosurgery Case Lessons·2022· 3 citedOpen Access
Amplified Cardiopulmonary Recordings: Music Therapy Legacy Intervention with Adult Oncology Patients and Their Families—A Preliminary Program Evaluation
Journal of Palliative Medicine·2022· 12 cited
CTIM-33. PHASE II TRIAL OF VACCINE IMMUNOTHERAPY IN PRIMARY GLIOBLASTOMA: ADJUNCTIVE AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE FROM IRRADIATED SELF-RENEWING AUTOLOGOUS TUMOR CELLS (AV-GBM-1)
Neuro-Oncology·2021· 1 citedOpen Access
331 Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts·2021Open Access
page 1 of 4Next →

Frequent Co-authors

Kathleen M. Egan(14), Reid C. Thompson(14), Burt Nabors(14), Jeffrey J. Olson(13), Robert Aiken(12), Santosh Kesari(9), Sajeel Chowdhary(8), Daniela A. Bota(7), Robert O. Dillman(7), James M. Markert(6), Charles E. Myers(6), Zachary Thompson(6), David Piccioni(6), Christopher Duma(6), Xiao–Tang Kong(6), Surasak Phuphanich(5), Joseph Landolfi(5), Jay‐Jiguang Zhu(5), Michael Glantz(5), David M. Peereboom(5)